Evaluating the Cost-effectiveness of Pharmaceuticals in Canada

Boothe, Katherine

doi:10.13162/hro-ors.v4i1.2796

HRO-ORS

2016

DOI: 10.13162/hro-ors.v4i1.2796

|View full text |Cite

Evaluating the Cost-effectiveness of Pharmaceuticals in Canada

Katherine Boothe

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“Getting to the Table”: Changing Ideas about Public and Patient Involvement in Canadian Drug Assessment

Boothe

2019

Journal of Health Politics, Policy and Law

View full text Add to dashboard Cite

Context: Involving patients and the public in health policy may contribute to legitimacy and accountability. However, tensions may arise between paradigms of scientific-evidence-based decision making and new ideas valuing inclusivity and patient experience when evaluating and allocating health resources. This article asks whether 10 years of experience with public and patient involvement in Canadian drug assessment has affected participants' ideas about how it works. Methods: The author surveyed the ideas of participants in the drug assessment process (members of expert committees, officials, and patient groups) as described in reports and hearings in 2005, 2007, and 2012 and conducted interviews in 2014 and 2016. Findings: The author found some consensus across groups of participants regarding the broad goals of health technology assessment (HTA) and the validity of some form of public and patient involvement. There were also important areas of disagreement and uncertainty about how public and patient involvement should be used in drug assessment and how much impact it has on deliberations and recommendations. Overall, uncertainly about the specific role for public and patient involvement in HTA limits the potential for ideational change among participants. Conclusions: These findings have implications for evaluation of public and patient involvement, the way we understand ideational change, and practical questions of communicating health resource decisions.

show abstract

“Getting to the Table”: Changing Ideas about Public and Patient Involvement in Canadian Drug Assessment

Boothe

2019

Journal of Health Politics, Policy and Law

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Evaluating the Cost-effectiveness of Pharmaceuticals in Canada

Cited by 1 publication

References 17 publications

“Getting to the Table”: Changing Ideas about Public and Patient Involvement in Canadian Drug Assessment

“Getting to the Table”: Changing Ideas about Public and Patient Involvement in Canadian Drug Assessment

Contact Info

Product

Resources

About